Protalix BioTherapeutics
PLX
#8915
Rank
ยฃ0.10 B
Marketcap
ยฃ1.30
Share price
-1.14%
Change (1 day)
-2.05%
Change (1 year)

Revenue for Protalix BioTherapeutics (PLX)

Revenue in 2025 (TTM): ยฃ47.17 Million

According to Protalix BioTherapeutics 's latest financial reports the company's current revenue (TTM ) is ยฃ46.49 Million. In 2024 the company made a revenue of ยฃ42.55 Million a decrease over the revenue in the year 2023 that were of ยฃ51.4 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Protalix BioTherapeutics from 1999 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) ยฃ47.17 M10.86%
2024 ยฃ42.55 M-17.23%
2023 ยฃ51.4 M30.55%
2022 ยฃ39.37 M38.6%
2021 ยฃ28.41 M-38.43%
2020 ยฃ46.14 M10.63%
2019 ยฃ41.7 M4%
2018 ยฃ40.1 M181.67%
2017 ยฃ14.23 M90.97%
2016 ยฃ7.45 M-261.73%
2015 -ยฃ4.61 Million-147.34%
2014 ยฃ9.73 M39.51%
2013 ยฃ6.97 M-67.23%
2012 ยฃ21.29 M230.28%
2011 ยฃ6.44 M56.82%
2010 ยฃ4.11 M1615.03%
2009 ยฃ0.23 M
2000 ยฃ0 M-100%
1999 ยฃ2.19 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Amicus Therapeutics
FOLD
ยฃ0.44 B 866.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
ยฃ2.01 B 4,230.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ47.12 B 101,252.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ12.59 B 26,980.78%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel